IsoRay SEC Filings

Type
Report
Date
4Insidertransaktion2/23/2023
DD-Formular2/21/2023
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben2/16/2023
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben2/16/2023
33-Formular2/13/2023
33-Formular2/13/2023
33-Formular2/13/2023
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben2/10/2023
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben2/6/2023
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben1/30/2023
DEFA14ADEFA14A-Formular1/12/2023
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben1/12/2023
DEFA14ADEFA14A-Formular12/14/2022
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben12/14/2022
DEFA14ADEFA14A-Formular12/6/2022
4Insidertransaktion12/5/2022
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben11/29/2022
4Insidertransaktion11/17/2022
424B5424B5-Formular11/16/2022
10-QQuartalsbericht11/14/2022
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben11/10/2022
DEFM14ADEFM14A-Formular11/7/2022
PREM14APREM14A-Formular10/25/2022
DEFA14ADEFA14A-Formular10/24/2022
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben10/24/2022
424B5424B5-Formular10/21/2022
10-KJahresbericht9/28/2022
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben9/28/2022
DEFA14ADEFA14A-Formular9/28/2022
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben9/28/2022
4/A4/A-Formular9/22/2022
4Insidertransaktion8/19/2022
4Insidertransaktion8/11/2022
4Insidertransaktion8/10/2022
4Insidertransaktion8/1/2022
4Insidertransaktion7/29/2022
4Insidertransaktion7/28/2022
4Insidertransaktion7/28/2022
4Insidertransaktion7/28/2022
4Insidertransaktion7/28/2022
4Insidertransaktion7/28/2022
4Insidertransaktion6/9/2022
4Insidertransaktion6/9/2022
4Insidertransaktion6/9/2022
SDSD-Formular5/26/2022
424B5424B5-Formular5/17/2022
10-QQuartalsbericht5/13/2022
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben5/10/2022
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben4/15/2022
424B5424B5-Formular2/10/2022
10-QQuartalsbericht2/9/2022
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben2/8/2022
S-8S-8-Formular1/28/2022
POS EXPOS EX-Formular1/28/2022
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben12/17/2021
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben12/9/2021
4Insidertransaktion11/24/2021
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben11/23/2021
424B5424B5-Formular11/12/2021
10-QQuartalsbericht11/10/2021
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben11/10/2021
DEFA14ADEFA14A-Formular10/25/2021
DEF 14ADEF 14A-Formular10/25/2021
424B5424B5-Formular10/1/2021
10-KJahresbericht9/27/2021
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben9/21/2021
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben9/15/2021
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben8/25/2021
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben8/3/2021
4Insidertransaktion7/6/2021
4Insidertransaktion7/6/2021
4Insidertransaktion7/6/2021
4Insidertransaktion7/6/2021
4Insidertransaktion7/6/2021
4Insidertransaktion7/6/2021
4Insidertransaktion7/6/2021
4Insidertransaktion7/6/2021
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben6/3/2021
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben5/28/2021
SDSD-Formular5/27/2021
424B5424B5-Formular5/19/2021
10-QQuartalsbericht5/14/2021
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben5/13/2021
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben3/23/2021
4Insidertransaktion3/16/2021
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben3/5/2021
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben2/12/2021
424B5424B5-Formular2/11/2021
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben2/9/2021
10-QQuartalsbericht2/9/2021
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben2/4/2021
424B5424B5-Formular2/4/2021
424B5424B5-Formular2/3/2021
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben2/3/2021
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben12/11/2020
4Insidertransaktion12/2/2020
424B5424B5-Formular11/17/2020
10-QQuartalsbericht11/13/2020
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben11/10/2020
4Insidertransaktion10/28/2020

IsoRay Documents 2026

This page contains all official documents and SEC filings for IsoRay stock (ISR, ISIN: US46489V1044). This includes annual reports (Form 10-K), quarterly reports (Form 10-Q), and insider transactions (Form 4). Currently 100 documents are available. Data is updated regularly to provide investors with a complete overview of IsoRay's regulatory filings.

IsoRay Stock analysis

IsoRay The company IsoRay Inc is a leading global company in the field of brachytherapy and specializes in the development of novel medical devices for the treatment of cancer. The company's history dates back to the 1980s when it was founded by a team of doctors and scientists. IsoRay Inc's business model is based on the research, development, and manufacturing of medical products used in the treatment of cancer. Brachytherapy is a particularly important focus. This involves a treatment method where radioactive seeds or sources are directly implanted into the tumor. The radiation destroys the cancer cells without damaging the surrounding tissue. IsoRay Inc's product range includes a variety of medical devices and accessories for conducting brachytherapy procedures. The company specializes in the development of high-tech products that enable precise and effective radiation therapy. This includes, for example, radioactive seeds that are directly implanted into the tumor or apparatuses that can selectively use radiation in specific structures of the body. A special focus of IsoRay Inc is computer-assisted planning of brachytherapy treatments. The tumor is precisely measured and the radiation sources are individually customized based on the data to achieve an optimal radiation dose. This planning is done using modern software and is an important factor for the successful treatment of cancer. In addition to research and development of medical products, IsoRay Inc also encompasses the production and distribution of these products. The company operates in more than 30 countries worldwide and collaborates closely with numerous clinics and practices to research and improve new technologies in the field of radiation therapy. One of IsoRay Inc's most well-known products is the "Cesium-131 Brachytherapy seed." This radioactive seed is particularly small and therefore ideal for targeted radiation therapy of tumors. It is used in almost all clinical areas worldwide and is considered particularly safe and effective. Other products of the company include the "Gladius™ Applicator Needle," a device for precise placement of radiation sources in tumors, as well as "Intraoperative Application Systems" that enable effective radiation therapy during surgery. Overall, IsoRay Inc is considered an innovative and successful company in the field of brachytherapy and radiation therapy. The constant development and improvement of its own products is a key factor for the company's success. High quality and close collaboration with research and practice are central to its operations.